Key Points GAAP revenue surpassed expectations, reaching $12.5 million in Q2 2025, Revenue reached $12.5 million, up approximately 45.3% from the prior year period. Net loss (GAAP) widened to $112.0 ...

The FDA has released a report to educate the public regarding the dangers of 7-OH and its distinction from the kratom plant ...

Humans are inherently pattern-seeking creatures. Our ancestors depended upon recognizing recurring patterns in nature to ...

U.S. health officials have told more than a half-dozen of the nation’s top medical organizations that they will no longer help establish vaccination recommendations. The government told ...

AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...

We recently published 10 Stocks Crushing With Whopping Double-Digit Gains. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one ...

From new payload linkers to artificial intelligence partnerships, advances in ADC pipelines push forward selective cancer therapies that minimize side effects.

Discover key takeaways from Moderna's Q2 2025 earnings call, including FDA approvals, cost reductions, pipeline strategies, and financial updates.

The FDA is requiring safety labeling changes to all opioid painkillers, to better highlight the risks posed by using the ...

A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...